Download PDF
Thromb Haemost 2021; 121(10): 1361-1366
DOI: 10.1055/s-0041-1725197
Stroke, Systemic or Venous Thromboembolism

Real-Life Management of Central and Branch Retinal Vein Occlusion: A Seven-Year Follow-Up Study

Alessandro Arrigo
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Anna Crepaldi
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Chiara Viganò
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Emanuela Aragona
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Rosangela Lattanzio
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Giovanni Scalia
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Antonio Giordano Resti
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Francesca Calcagno
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Adelaide Pina
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Hassan Farah Rashid
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Francesco Bandello
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
,
Maurizio Battaglia Parodi
1   Department of Ophthalmology, IRCCS San Raffaele Hospital, University Vita-Salute, Milan, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Retinal vein occlusion is the second most common retinal vascular pathology after diabetic retinopathy and a major cause of vision impairment. Nowadays, both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) can be well-managed by intravitreal treatments. However, considering the long-life expectance of the patients, few data are present in the literature about the very long-term outcome of CRVO and BRVO. The present study was an interventional, retrospective analysis of the morphological and functional long-term outcome of CRVO and BRVO patients, followed in an Italian referral center. We collected data from 313 eyes (178 CRVO eyes and 135 BRVO eyes). Mean follow-up was 45 ± 25 months (range 12–84 months). Both CRVO and BRVO eyes experience a significant visual acuity improvement secondary to anti-vascular endothelial growth factor/dexamethasone treatments (from 0.57 ± 0.25 to 0.41 ± 0.24 LogMAR in CRVO and from 0.53 ± 0.42 to 0.30 ± 0.41 LogMAR in BRVO, respectively) (p < 0.01). Also, central macular thickness (CMT) resulted significant recovery at the end of the follow-up (from 585.54 ± 131.43 to 447.88 ± 245.07 μm in CRVO and from 585.54 ± 131.43 to 447.88 ± 245.07 μm in BRVO, respectively) (p < 0.01). CRVO eyes received a mean of 10.70 ± 4.76 intravitreal treatments, whereas BRVO underwent 9.80 ± 5.39 injections over the entire 7-year follow-up. Our analyses highlighted different time points indicating the best obtainable improvement. This was the first year for CRVO (12-month follow-up) and the second year for BRVO (24-month follow-up). After these two time points, both visual acuity and CMT resulted stable up to the end of the follow-up. Ischemia was associated with significantly worse outcome.

Keywords

central retinal vein occlusion - branch retinal vein occlusion - optical coherence tomography - real-life study - intravitreal injection


Publication History

Received: 14 December 2020

Accepted: 23 January 2021

Article published online:
11 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117 (04) 429-441
    CrossrefPubMedGoogle Scholar
  • 2 Rogers S, McIntosh RL, Cheung N. et al; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117 (02) 313-319
    CrossrefPubMedGoogle Scholar
  • 3 Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res 2014; 41: 1-25
    CrossrefPubMedGoogle Scholar
  • 4 Noma H, Funatsu H, Sakata K. et al. Macular microcirculation and macular oedema in branch retinal vein occlusion. Br J Ophthalmol 2009; 93 (05) 630-633
    CrossrefPubMedGoogle Scholar
  • 5 Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol 2011; 152 (04) 669-677
    CrossrefPubMedGoogle Scholar
  • 6 Campochiaro PA, Brown DM, Awh CC. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118 (10) 2041-2049
    CrossrefPubMedGoogle Scholar
  • 7 Kinge B, Stordahl PB, Forsaa V. et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010; 150 (03) 310-314
    CrossrefPubMedGoogle Scholar
  • 8 Haller JA, Bandello F, Belfort Jr R. et al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117 (06) 1134-1146
    CrossrefPubMedGoogle Scholar
  • 9 Haller JA, Bandello F, Belfort Jr R. et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118 (12) 2453-2460
    CrossrefPubMedGoogle Scholar
  • 10 Heier JS, Campochiaro PA, Yau L. et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119 (04) 802-809
    CrossrefPubMedGoogle Scholar
  • 11 Campochiaro PA, Sophie R, Pearlman J. et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014; 121 (01) 209-219
    CrossrefPubMedGoogle Scholar
  • 12 Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P. Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data. Retina 2018; 38 (03) 559-568
    CrossrefPubMedGoogle Scholar
  • 13 Spooner K, Fraser-Bell S, Hong T, Chang AA. Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ Open Ophthalmol 2019; 29 (04) e000249
    CrossrefPubMedGoogle Scholar
  • 14 Maggio E, Mete M, Maraone G, Attanasio M, Guerriero M, Pertile G. Intravitreal injections for macular edema secondary to retinal vein occlusion: long-term functional and anatomic outcomes. J Ophthalmol 2020; 2020: 7817542
    CrossrefPubMedGoogle Scholar
  • 15 Brown DM, Campochiaro PA, Singh RP. et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117 (06) 1124-1133
    CrossrefPubMedGoogle Scholar
  • 16 Boyer D, Heier J, Brown DM. et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012; 119 (05) 1024-1032
    CrossrefPubMedGoogle Scholar
  • 17 Brown DM, Heier JS, Clark WL. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155 (03) 429-437
    CrossrefPubMedGoogle Scholar
  • 18 Heier JS, Clark WL, Boyer DS. et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121 (07) 1414-1420
    CrossrefPubMedGoogle Scholar
  • 19 Holz FG, Roider J, Ogura Y. et al. VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013; 97 (03) 278-284
    CrossrefPubMedGoogle Scholar
  • 20 Korobelnik JF, Holz FG, Roider J. et al; GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014; 121 (01) 202-208
    CrossrefPubMedGoogle Scholar
  • 21 Ogura Y, Roider J, Korobelnik JF. et al; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 2014; 158 (05) 1032-1038
    CrossrefPubMedGoogle Scholar
  • 22 Battaglia Parodi M, Iacono P, Sacconi R, Parravano M, Varano M, Bandello F. Dexamethasone implant for macular edema secondary to central retinal vein occlusion in patients younger than 50 years. Retina 2015; 35 (07) 1381-1386
    CrossrefPubMedGoogle Scholar
  • 23 Larsen M, Waldstein SM, Priglinger S. et al; CRYSTAL Study Group. Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study. Ophthalmol Retina 2018; 2 (02) 134-142
    CrossrefPubMedGoogle Scholar
  • 24 Brown DM, Campochiaro PA, Bhisitkul RB. et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118 (08) 1594-1602
    CrossrefPubMedGoogle Scholar
  • 25 Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL. RAVE Study Group. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the Rubeosis anti-VEGF (RAVE) trial. Retina 2014; 34 (09) 1728-1735
    CrossrefPubMedGoogle Scholar
  • 26 Rezar S, Eibenberger K, Bühl W, Georgopoulos M, Schmidt-Erfurth U, Sacu S. Macula Study Group Vienna. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol 2015; 93 (08) 719-725
    CrossrefPubMedGoogle Scholar
  • 27 Clark WL, Boyer DS, Heier JS. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016; 123 (02) 330-336
    CrossrefPubMedGoogle Scholar
  • 28 Tadayoni R, Waldstein SM, Boscia F. et al; BRIGHTER study group. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 2016; 123 (06) 1332-1344
    CrossrefPubMedGoogle Scholar
  • 29 Tadayoni R, Waldstein SM, Boscia F. et al; BRIGHTER Study Group. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 2017; 124 (12) 1778-1787
    CrossrefPubMedGoogle Scholar
  • 30 Battaglia Parodi M, Romano F, Arrigo A. et al. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital. Eur J Ophthalmol 2020; 30 (06) 1461-1466
    CrossrefPubMedGoogle Scholar
  • 31 Chatziralli I, Theodossiadis G, Parikakis E, Mitropoulos PG, Theodossiadis P. Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmic Res 2017; 58 (04) 203-208
    CrossrefPubMedGoogle Scholar
  • 32 Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol 2018; 63 (06) 816-850
    CrossrefPubMedGoogle Scholar